Clinical significance of SH2B1 adaptor protein expression in non-small cell lung cancer

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 5, 2012, Pages 2355-2362

  Zhang, Hang ^a   Duan, Chao Jun ^a   Chen, Wei ^a   Wang, Shao Qiang ^a   Zhang, Sheng Kang ^a   Dong, Shuo ^a   Cheng, Yuan Da ^a   Zhang, Chun Fang ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Metastasis; Non small cell lung cancer; Prognosis; SH2B1

Indexed keywords

MESSENGER RNA; SH2B1 PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ADENOCARCINOMA; ARTICLE; CANCER GRADING; CANCER STAGING; CELL CULTURE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; FOLLOW UP; GENETICS; HUMAN; LUNG; LUNG NON SMALL CELL CANCER; LUNG TUMOR; LYMPH NODE METASTASIS; MALE; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TUMOR RECURRENCE; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOCARCINOMA; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELLS, CULTURED; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE;

EID: 84872686445     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.5.2355     Document Type: Article

References (47)

1. Ahmad I, Singh LB, Foth M, et al (2011). K-Ras and β-catenin mutations cooperate with Fgfr3 mutations in mice to promote tumorigenesis in the skin and lung, but not in the bladder. Dis Model Mech, 4, 548-55.
2. Bahrenberg G, Behrmann I, Barthel A, et al (2002). Identification of the critical sequence elements in the cytoplasmic domain of leptin receptor isoforms required for Janus kinase/signal transducer and a ctivator of transcription activation by receptor heterodimers. Mol Endocrinol, 16, 859-72.
3. Balch CM, Gershenwald JE, Soong SJ, et al (2009). Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol, 27, 6199-206.
4. Cappellen D, De Oliverira C, Ricol D, et al (1999). Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet, 23, 18-20.
5. Chen L, Carter-Su C (2004). Adapter protein SH2-B beta undergoes nucleocytoplasmic shuttling: implications for nerve growth factor induction of neuronal differentiation. Mol Cell Biol, 24, 3633-47.
6. Chesi M, Nardini E, Brents LA, et al (1997). Frequent translocation t (4;14) (p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet, 16, 260-4.
7. Cosaceanu D, Carapancea M, Castro J, et al (2005). Modulation of response to radiation of human lung cancer cells following insulin-like growth factor-1 receptor inactivation. Cancer Lett, 222, 173-81.
8. Diakonova M, Gunter DR, Herrington J and Carter-Su C (2002). SH2-Bbeta is a Rac-binding protein that regulates cell motility. J Biol Chem, 277, 10669-77.
9. Donatello S, Fiorino A, Degl'Innocenti D, et al (2007). SH2B1beta adaptor is a key enhancer of RET tyrosine kinase signaling. Oncogene, 26, 6546-59.
10. Duan C, Li M, Rui L (2004). SH2-B promotes insulin receptor substrate 1 (IRS1)-and IRS2-mediated activation of the phosphatidylinositol 3-kinase pathway in response to leptin. J Biol Chem, 279, 43684-91.
11. Eggert A, Ikegaki N, Liu X, et al (2000). Molecular dissection of TrkA signal transduction pathways mediating differentiation in human neuroblastoma cells. Oncogene, 19, 2043-51.
12. Favoni RE, de Cupis A, Ravera F, et al (1994). Expression and function of the insulin-like growth factor I system in human non-small-cell lung cancer and normal lung cell lines. Int J Cancer, 56, 858-66.
13. Firedman E, Gejman PV, Martin GA, McCormick F (1993). Nonsense mutations in the C-terminal SH2 region of the GTPase actvating protein (GAP) gene in human tumours. Nat Genet, 5, 242-7.
14. Fisseler-Eckhoff A (2009). [New TNM classification of malignant lung tumors 2009 from a pathology perspective]. Pathologe, 30, 193-9.
15. Garcia R, Jove R (1998). Activation of STAT transcription factors in oncogenic tyrosine kinase signaling. J Biomed Sci, 5, 79-85.
16. Herrington J, Diakonova M, Rui L, et al (2000). SH2-B is required for growth hormone-induced actin reorganization. J Biol Chem, 275, 13126-33.
17. Hua JJ, Pan WF, Jiang J, et al (2010). Expression and significance of SH2-B in ovarian serous carcinoma. Cancer Res Prev Treat, 37, 693-5 (in Chinese).
18. Huang DM, Li JG, Chen Y, et al (2010). SH2-B enhances proliferation of colon cancer HT 229 cells. [in Chinese] Chinese J General Surg, 19, 769-73.
19. Iseki M, Takaki S, Takatsu K (2000). Molecular cloning of the mouse APS as a member of the Lnk family adaptor proteins. Biochem Biophys Res Commun, 272, 45-54.
20. Ju YS, Lee WC, Shin JY, et al (2012). A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res, 22, 436-45.
21. Kong M, Wang CS, Donoghue DJ (2002). Interaction of fibroblast growth factor receptor 3 and the adapter protein SH2-B. A role in STAT5 activation. J Biol Chem, 277, 15962-70.
22. Koukourakis MI, Giatromanolaki A, O'Byme KJ, et al (1997). Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in nonsmall-cell lung cancer. Br J Cancer, 75, 477-81.
23. Lacronique V, Boureux A, Valle VD, et al (1997). A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science, 278, 1309-12.
24. Li JG, Hua JJ, Huang DM, et al (2010). SH2-B expression in colon cancer and its clinical significance. China J Modern Med, 20, 2004-7 (in Chinese).
25. Oneyama C, Ikeda J, Okuzaki D, et al (2011). MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways. Oncogene, 30, 3489-501.
26. Osborne MA, Dalton S, Kochan JP (1995). The yeast tribrid system-genetic detection of trans-phosphorylated ITAM-SH2-interactions. Biotechnology, 13, 1474-8.
27. Pawson T, Scott JD (1997). Signaling through scaffold, anchoring and adaptor proteins. Science, 278, 2075-80.
28. Qian X, Riccio A, Zhang Y, Ginty DD (1998). Identification and characterization of novel substrates of Trk receptors in developing neurons. Neuron, 21, 1017-29.
29. Reddy C, Chilla D, Boltax J (2011). Lung cancer screening: a review of available data and current guidelines. Hosp Pract, 39, 107-12.
30. Ren D, Li M, Duan C, Rui L (2005). Identification of SH2-B as a key regulator of leptin sensitivity, energy balance and body weight in mice. Cell Metab, 2, 95-104.
31. Riedel H, Yousaf N, Zhao Y, et al (2000). PSM, a mediator of PDGF-BB-, IGF-I-, and insulin-stimulated mitogenesis. Oncogene, 19, 39-50.
32. Rui L, Herrington J, Carter-Su C (1999). SH2-B, a membrane-associated adapter, is phosphorylated on multiple serines/threonines in response to nerve growth factor by kinases within the MEK/ERK cascade. J Biol Chem, 274, 26485-92.
33. Rui L, Mathews LS, Hotta K, et al (1997). Identification of SH2-Bbeta as a substrate of the tyrosine kinase JAK2 involved in growth hormone signaling. Mol Cell Biol, 17, 6633-44.
34. Seki Y, Suzuki N, Imaizumi M, et al (2004). STAT3 and MAPK in human lung cancer tissues and suppression of oncogenic growth by JAB and dominant negative STAT. Int J Oncol, 24, 931-4.
35. Soderdahl G, Betsholtz C, Johanson A, et al (1998). Differential expression of platelet-derived growth factor and tranforming growth factor genes in small-and non-small cell human lung carcinoma line. Int J Cancer, 41, 636-41.
36. Somasundar P, McFadden DW, Hileman SM, Vona-Davis L (2004). Leptin is a growth factor in cancer. J Surg Res, 116, 337-49.
37. Suzuki K, Mizutani M, Hitomi Y, et al (2002). Association of SH2-B to phosphorylated tyrosine residues in the activation loop of TrkB. Res Commun Mol Pathol Pharmacol, 111, 27-39.
38. Tang FQ, Li JG, Chen Y, et al (2011). Relationship of SH2-B and motility and invasion of colon cancer cells. Chin J Cancer Prev Treat, 18, 1-4 (in Chinese).
39. Tanizaki J, Okamoto I, Sakai K and Nakagawa K (2011). Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification. Br J Cancer, 105, 807-13.
40. Tsuchiya T, Shimizu H, Horie T, Mori M (1999). Expression of leptin receptor in lung: leptin as a growth factor. Eur J Pharmacol, 365, 273-9.
41. Wang J, Riedel H (1998). Insulin-like growth factor-I receptor and insulin receptor association with a Src homology-2 domain-containing putative adapter. J Biol Chem, 273, 3136-9.
42. Wang X, Chen L, Maures TJ, et al (2004). SH2-B is a positive regulator of nerve growth factor-mediated activation of the Akt/Forkhead pathway in PC12 Cells. J Biol Chem, 279, 133-41.
43. Yousaf N, Deng Y, Kang Y, Riedel H (2001). Four PSM/SH2-B alternative splice variants and their differential roles in mitogenesis. J Biol Chem, 276, 40940-8.
44. Zhang CF, Chen W, Huang QH, et al (2009). The expression of SH2-B in nonsmall-cell lung cancer. Chin J Exp Surg, 26, 1360-2 (in Chinese).
45. Zhang X, Zhang J, Wang L, et al (2007). Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice. BMC Cancer, 7, 149.
46. Zhang Y, Zhu W, Wang YG, et al (2006). Interaction of SH2-Bbeta with RET is involved in signaling of GDNF-induced neurite outgrowth. J Cell Sci, 119, 1666-76.
47. Zhou SY, Cantley LC (2004). ZIP codes for delivering SH2 domains. Cell, 116, 41-3.